Funding for this research was provided by:
Active and Assisted Living programme (AAL-call-068-2017)
AGE-WELL (AW-AAL 2017)
Received: 16 April 2020
Accepted: 16 August 2020
First Online: 28 August 2020
Ethics approval and consent to participate
: The study has been performed in accordance with the Declaration of Helsinki. It has been approved by the Research Ethics Board (REB) in each country: Switzerland: REB Canton de Vaud (application #2018–01898, last approval December 4 2018); Canada: REB vieillissement-neuroimagerie of the CIUSSS-CSMTL (application #18–19-29, last approval December 14 2018); Belgium: REB Cliniques Universitaires Saint-Luc, UCLouvain, Bruxelles (application #B403201941535, last approval October 15 2019). Any modifications to the protocol which may impact on the conduct of the study, potential benefit of the patient or may affect patient safety, including changes of study objectives, study design, patient population, sample sizes, study procedures, or significant administrative aspects will require a formal amendment to the protocol. Such amendment will be approved by the different REB before implementation.Participants and their informants will sign an informed consent form at their first visit for screening.
: Not applicable.
: SB has been a consultant for research development on the prevention of Alzheimer’s disease for the Fondation IUGM (2016) and for Sojecci (2017 to current), and for the development of a cognitive stimulation programme for the Centre de promotion de la Santé Avant Âge (2015). She has intellectual property rights on the ‘Programme de Stimulation pour une santé cognitive, Memoria, Batterie d’évaluation de la mémoire Côte-des-Neiges’ and ‘MEMO, Méthode d’Entrainement pour une Mémoire Optimale’.MBA, DPM and SC are employees of MindMaze SA.The remaining authors declare that they have no competing interest.